Hypothesis

Rapamycin extends lifespan not by repairing damage but by sustaining a cellular perception of nutrient scarcity; therefore, interventions that restore metabolic flexibility—such as L‑carnitine supplementation—should attenuate or abolish rapamycin‑dependent longevity benefits.

Mechanistic Rationale

Rapamycin inhibits mTORC1, shifting muscle metabolism toward fatty acid oxidation and increasing autophagy, mimicking the metabolic state of caloric restriction (CR) [1][2]. This shift reduces acetyl‑CoA availability, lowers protein synthesis, and activates stress‑responsive pathways (AMPK, SIRT1, FOXO) that promote survival under famine. Carnitine is essential for transporting long‑chain fatty acids into mitochondria; its supplementation reverses age‑related carnitine deficiency, boosts fatty acid oxidation, and increases acetylcarnitine efflux [2][3]. By replenishing the carnitine shuttle, L‑carnitine restores substrate flexibility and raises acetyl‑CoA levels, which would counteract the scarcity signal generated by mTORC1 inhibition. If the longevity effect hinges on maintaining a low‑energy, low‑acetyl‑CoA milieu, then rescuing acetyl‑CoA availability should blunt downstream autophagy and stress‑response activation, revealing whether rapamycin’s benefits are purely simulative.

Predictions

1. In aged mice, rapamycin alone will increase lifespan, hepatic autophagy markers (LC3‑II/I, p62 degradation), and circulating FGF21 (a CR‑like hormone).
2. Co‑administration of L‑carnitine with rapamycin will normalize muscle acetyl‑carnitine/ free‑carnitine ratios, increase mitochondrial acetyl‑CoA, and reduce autophagy induction compared with rapamycin alone.
3. The lifespan extension observed with rapamycin will be significantly shortened in the rapamycin + carnitine group, approaching that of control mice.
4. Immune phenotypes previously altered by rapamycin (e.g., reduced naïve T‑cell output) [4] will be partially restored when carnitine is added, indicating that the immunosuppressive trade‑off is also scarcity‑signal dependent.

Experimental Design

• Animals: 20‑month‑old C57BL/6J mice, n=30 per group.
• Groups: (1) Vehicle control, (2) Rapamycin (14 ppm diet), (3) L‑carnitine (1 % w/w drinking water), (4) Rapamycin + L‑carnitine.
• Duration: 12 months monitoring survival; interim assessments at 4, 8, and 12 months.
• Readouts: Survival curves, muscle acylcarnitine profiling (LC‑MS), hepatic LC3‑II/I and p62 via Western blot, serum FGF21 and ketone bodies, flow cytometric analysis of splenic naïve/memory T‑cell subsets.
• Statistical Analysis: Kaplan‑Meier with log‑rank test for survival; two‑way ANOVA with Tukey post‑hoc for biochemical and immunological endpoints.

Potential Outcomes and Interpretation

If rapamycin + carnitine mice show diminished autophagy, lowered FGF21, and no survival advantage over controls, the data would support the hypothesis that rapamycin’s lifespan extension depends on maintaining a perceived scarcity state rather than on direct damage repair. Conversely, if lifespan remains extended despite carnitine‑mediated metabolic rescue, it would suggest that rapamycin engages downstream repair mechanisms (e.g., enhanced proteostasis or DNA‑damage response) that are not fully reversed by restoring acetyl‑CoA flux. Either outcome clarifies whether pharmacologically induced longevity is a genuine amelioration of aging or a sophisticated mimicry of adversity.